Spots Global Cancer Trial Database for myeloid malignancies
Every month we try and update this database with for myeloid malignancies cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Phase I/II Study of Engineered T Cell Receptor-Modified NK Cells Targeting PRAME in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Myeloid Malignancies | NCT06383572 | Lymphodepleting... Myeloid Maligna... | Cyclophosphamid... Fludarabine pho... Decitabine | 18 Years - 75 Years | M.D. Anderson Cancer Center | |
| Phase I/II Study of Engineered T Cell Receptor-Modified NK Cells Targeting PRAME in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Myeloid Malignancies | NCT06383572 | Lymphodepleting... Myeloid Maligna... | Cyclophosphamid... Fludarabine pho... Decitabine | 18 Years - 75 Years | M.D. Anderson Cancer Center | |
| Imetelstat Sodium in Treating Participants With Primary or Secondary Myelofibrosis | NCT01731951 | Primary Myelofi... Secondary Myelo... Myeloid Maligna... | Imetelstat | 18 Years - | Geron Corporation | |
| Ph2 NK Cell Enriched DCIs w/wo RLR9 Agonist, DUK-CPG-001 From Donors Following Allogeneic SCT | NCT02452697 | Myeloid Maligna... Lymphoid Malign... | NK Cell enriche... NK-DLI + DUK-CP... | 18 Years - | Duke University | |
| A Phase I Trial of Alloreactive Cell Infusion Following Transplantation of Haplotype Cells in Patients With Myeloid Malignancies | NCT00569179 | Leukemia, Myelo... Leukemia, Lymph... Myelodysplastic... Leukemia, Myelo... | CliniMACS CD34 ... | 18 Years - 65 Years | Indiana University | |
| A Study of LNK01002 in Patients With Primary or Secondary Myelofibrosis,Polycythemia Vera or Acute Myeloid Leukemia | NCT04896112 | Acute Myeloid L... Primary Myelofi... Post-polycythem... Post-essential ... Polycythemia Ve... | LNK01002 | 18 Years - 99 Years | Lynk Pharmaceuticals Co., Ltd | |
| A Clinical Research of CD33-Targeted CAR-T in Myeloid Malignancies | NCT02958397 | Myeloid Maligna... | Anti-CD33-CAR-t... | 14 Years - 75 Years | Southwest Hospital, China | |
| A Pilot Study to Evaluate the Feasibility of Post-Hematopoietic Stem Cell Transplant Prophylaxis With Decitabine Combined With Filgrastim for Children and Young Adults With AML, MDS and Related Myeloid Malignancies | NCT05796570 | Acute Myeloid L... Myelodysplastic... Myeloid Maligna... MDS Inherited Bone ... Myeloid Neoplas... Aml | Decitabine Filgrastim | 1 Year - 39 Years | Dana-Farber Cancer Institute | |
| Phase II Hedgehog Inhibitor for Myelodysplastic Syndrome (MDS) | NCT01842646 | Myelodysplastic... Chronic Myelomo... | PF-04449913 | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| A Pilot Study to Evaluate the Feasibility of Post-Hematopoietic Stem Cell Transplant Prophylaxis With Decitabine Combined With Filgrastim for Children and Young Adults With AML, MDS and Related Myeloid Malignancies | NCT05796570 | Acute Myeloid L... Myelodysplastic... Myeloid Maligna... MDS Inherited Bone ... Myeloid Neoplas... Aml | Decitabine Filgrastim | 1 Year - 39 Years | Dana-Farber Cancer Institute | |
| Off-the-shelf NK Cells + SCT for Myeloid Malignancies | NCT05115630 | Myeloid Maligna... Acute Myeloid L... Myelodysplastic... Chronic Myeloid... | Cyclophosphamid... Mesna Filgrastim Melphalan Fludarabine pho... Tacrolimus Mycophenolate m... Total Body Irra... | 18 Years - 70 Years | M.D. Anderson Cancer Center | |
| Phase II Hedgehog Inhibitor for Myelodysplastic Syndrome (MDS) | NCT01842646 | Myelodysplastic... Chronic Myelomo... | PF-04449913 | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| A Clinical Research of LeY-Targeted CAR-T in Myeloid Malignancies | NCT02958384 | Myeloid Maligna... | Anti-LeY-CAR-tr... | 14 Years - 75 Years | Southwest Hospital, China | |
| Fractionated Busulfan Conditioning Regimen for Allo-HSCT in Non-remission Myeloid Malignancies | NCT05807659 | Myeloid Maligna... | fractionated bu... | 18 Years - 65 Years | Sichuan University | |
| A Phase I Trial of Alloreactive Cell Infusion Following Transplantation of Haplotype Cells in Patients With Myeloid Malignancies | NCT00569179 | Leukemia, Myelo... Leukemia, Lymph... Myelodysplastic... Leukemia, Myelo... | CliniMACS CD34 ... | 18 Years - 65 Years | Indiana University | |
| Phase II Hedgehog Inhibitor for Myelodysplastic Syndrome (MDS) | NCT01842646 | Myelodysplastic... Chronic Myelomo... | PF-04449913 | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
